Redx Pharma Plc Stock price

Equities

REDX

GB00BSNB6S51

Biotechnology & Medical Research

Delayed London S.E. 11:49:43 2024-03-28 am EDT 5-day change 1st Jan Change
18.95 GBX +1.07% Intraday chart for Redx Pharma Plc -7.56% -13.86%
Sales 2024 * 13.73M 17.35M Sales 2025 * 1.25M 1.58M Capitalization 72.93M 92.15M
Net income 2024 * -25M -31.59M Net income 2025 * -43M -54.33M EV / Sales 2024 * 4.77 x
Net cash position 2024 * 7.41M 9.36M Net Debt 2025 * 28.99M 36.63M EV / Sales 2025 * 81.4 x
P/E ratio 2024 *
-3.02 x
P/E ratio 2025 *
-1.85 x
Employees 101
Yield 2024 *
-
Yield 2025 *
-
Free-Float 81.87%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.07%
1 week-7.56%
Current month+2.43%
1 month+2.43%
3 months-13.86%
6 months-27.12%
Current year-13.86%
More quotes
1 week
18.00
Extreme 18
20.20
1 month
17.00
Extreme 17
22.85
Current year
17.00
Extreme 17
34.11
1 year
17.00
Extreme 17
37.90
3 years
17.00
Extreme 17
129.90
5 years
4.50
Extreme 4.5
129.90
10 years
3.50
Extreme 3.5
129.90
More quotes
Managers TitleAgeSince
Chief Executive Officer - 18-05-31
Director of Finance/CFO - 21-05-04
Chief Operating Officer 46 18-11-18
Members of the board TitleAgeSince
Director/Board Member 70 22-01-26
Director/Board Member 65 23-09-05
Director/Board Member 75 17-11-02
More insiders
Date Price Change Volume
24-03-28 18.95 +1.07% 61 901
24-03-27 18.75 0.00% 37,638
24-03-26 18.75 -3.85% 64,993
24-03-25 19.5 0.00% 115,284
24-03-22 19.5 -4.88% 73,269

Delayed Quote London S.E., March 28, 2024 at 11:49 am EDT

More quotes
Redx Pharma Plc is a United Kingdom-based clinical-stage biotechnology company. The Company is focused on the discovering and developing of novel, small molecule, targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis. The Company's product pipeline includes RXC004, RXC007 (ROCK2 selective inhibitor) and RXC008. RXC004 is a potent, selective, oral small molecule inhibitor of the enzyme Porcupine, a key activator of Wnt-ligands in the Wnt signaling pathway. Selective ROCK2 inhibitor for the treatment of interstitial lung diseases with an initial study in idiopathic pulmonary fibrosis. RXC007 is a potent, selective and orally active inhibitor that targets Rho-Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2), which sits at a nodal point in cell signaling pathways, central to fibrosis. RXC008 for the treatment of fibrostenotic Crohn's disease.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1875 GBP
Average target price
1.3 GBP
Spread / Average Target
+593.33%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Redx Pharma Plc - London S.E.